Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells

• Published in: Inflammatory bowel diseases Vol. 30; no. 5; pp. 704 - 717
• Main Authors: Boden, Elisa K, Kongala, Ramya, Hindmarch, Duncan C, Shows, Donna M, Juarez, Julius G, Lord, James D
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 02.05.2024
• Subjects: Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Biopsy; Case-Control Studies; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - immunology; Colitis, Ulcerative - pathology; Colon - immunology; Colon - metabolism; Colon - pathology; Crohn Disease - drug therapy; Crohn Disease - immunology; Crohn Disease - pathology; Cross-Sectional Studies; Dendritic cells; Dendritic Cells - immunology; Editor's Choice; Female; Gastrointestinal Agents - pharmacology; Gastrointestinal Agents - therapeutic use; Humans; Integrins - metabolism; Intestinal Mucosa - drug effects; Intestinal Mucosa - immunology; Leading Off; Lymphocytes; Male; Memory T Cells - immunology; Middle Aged; Monoclonal antibodies; vedolizumab; integrin; T cell; dendritic cell

Abstract Background Vedolizumab, an antibody blocking integrin α4β7, is a safe and effective therapy for Crohn’s disease and ulcerative colitis. Blocking α4β7 from binding its cognate addressin MAdCAM-1 on intestinal blood vessel endothelial cells prevents T cells from migrating to the gut mucosa in...